|
KMID : 0387720210320010011
|
|
Korean Journal of Blood Transfusion
2021 Volume.32 No. 1 p.11 ~ p.21
|
|
|
Blood Coagulation Products and Other Hemostatic Agents
|
|
Kim Jae-Hyun
|
|
|
Abstract
|
|
|
|
Normal hemostasis is achieved by the concerted interactions of vascular endothelial cells, platelets, and plasma coagulation factors. The blood coagulation mechanism involves the regulated sequence of proteolytic activation of a series of blood coagulation zymogen factors. Some of these blood coagulation factors, either purified from human plasma or produced by recombinant DNA technologies, are used to treat patients with congenital or acquired deficiencies in coagulation factors. Furthermore, blood coagulation products are used for perioperative coagulation management and toical hemostatic agents to help control bleeding during surgery. Thus, the coagulant blood products have great medical importance to treat life-threatening bleeding disorders and serious medical conditions. This review provides an overview and summarizes the clinical use of coagulant blood products.
|
|
|
KEYWORD
|
|
|
Clotting factors, Coagulant blood factors, Plasma-derived medicinal products, Recombinant DNA technologies, Indications
|
|
|
FullTexts / Linksout information
|
|
|
|
|
Listed journal information
|
|
  
|